Why Kyle Schwarber's $150M Deal Is a Major Risk for Philadelphia Phillies

Drew ThirionDrew Thirion|published: Wed 10th December, 10:19 2025
Oct 9, 2025; Los Angeles, California, USA; Philadelphia Phillies left fielder Kyle Schwarber (12) reacts after a double in the first inning against the Los Angeles Dodgers during game four of the NLDS round for the 2025 MLB playoffs at Dodger Stadium. Mandatory Credit: Jayne Kamin-Oncea-Imagn ImagesOct 9, 2025; Los Angeles, California, USA; Philadelphia Phillies left fielder Kyle Schwarber (12) reacts after a double in the first inning against the Los Angeles Dodgers during game four of the NLDS round for the 2025 MLB playoffs at Dodger Stadium. Mandatory Credit: Jayne Kamin-Oncea-Imagn Images

The Philadelphia Phillies made the most significant signing of the offseason so far by retaining their star DH, Kyle Schwarber, on a five-year, $150 million deal. Schwarber is coming off a career season in which he slashed .240/.365/.563 and crushed an NL-leading 56 home runs.

This move was a no-brainer for the Phillies. Across the league, everyone who’s played with Schwarber raves about him. Beyond being a tremendous locker-room presence, he has turned himself into a legitimate superstar since leaving the Cubs. Since arriving in Philly, he has never posted an OPS below .817, has hit at least 38 home runs every season, has played 150+ games every year, and just finished second in MVP voting.

But Schwarber isn’t returning solely because of brotherly love — this is the biggest contract of his career and locks him in until age 37. The Phillies have a little youth bubbling in the system, but this roster is aging, and committing long-term money to an older DH carries real risk.

GM Dave Dombrowski is currently trying to move Nick Castellanos’ contract, while also attempting to retain J.T. Realmuto (34) and trade-deadline acquisition Harrison Bader (31). Zack Wheeler, entering his age-36 season, is recovering from the blood clot issue that sidelined him down the stretch and kept him out of the postseason. While Wheeler’s recovery appears to be progressing, it’s another aging star contributing to the uncertainty entering 2026.

Complicating matters further: the NL East is only getting stronger, shrinking the window for this Phillies core. Re-signing Schwarber is entirely defensible — even admirable — but this deal alone won’t keep the team competitive. More moves must be made for the contract to pay off.

The biggest question looms over the rotation. If Aaron Nola doesn’t rebound, who slots in behind a recovering Wheeler and Cristopher Sánchez? Jesús Luzardo is a solid back-end arm, and Taijuan Walker can fill innings, but that group doesn’t stack up against contenders like the Dodgers.

Top pitching prospect Andrew Painter remains a huge variable. Once a future ace, he posted a 5.40 ERA in AAA in 2025, and the rest of the organization doesn’t have many arms ready to contribute in 2026.

Philadelphia had to bring Schwarber back. But how this contract ages — especially for a player who isn’t exactly a “genetic freak” — is a major question. It’s a lot of money locked into a DH on a roster with pressing needs, particularly in the rotation.

Of course, Schwarber might make all of this look foolish with another massive season in the heart of the Phillies’ lineup.

home why-kyle-schwarbers-150m-deal-is-a-major-risk-for-philadelphia-phillies